Free Trial

Feedback (FDBK) Competitors

Feedback logo
GBX 11.71 -0.04 (-0.34%)
As of 06:25 AM Eastern

FDBK vs. RENX, COG, INHC, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS

Should you be buying Feedback stock or one of its competitors? The main competitors of Feedback include Renalytix (RENX), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.

Feedback vs. Its Competitors

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Feedback has a net margin of -279.16% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-279.16% -39.71% -22.99%
Renalytix -1,191.75%293.20%-93.54%

In the previous week, Feedback had 2 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for Feedback and 0 mentions for Renalytix. Renalytix's average media sentiment score of 0.00 beat Feedback's score of -0.10 indicating that Renalytix is being referred to more favorably in the news media.

Company Overall Sentiment
Feedback Neutral
Renalytix Neutral

Feedback has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Feedback has higher earnings, but lower revenue than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£1.19M4.30-£10.84M-£0.24-47.91
Renalytix£2.37M10.58-£109.93M-£0.16-47.38

92.3% of Feedback shares are held by institutional investors. Comparatively, 25.6% of Renalytix shares are held by institutional investors. 8.0% of Feedback shares are held by company insiders. Comparatively, 6.7% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Renalytix beats Feedback on 7 of the 13 factors compared between the two stocks.

Get Feedback News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDBK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£5.13M£344.35M£5.74B£2.57B
Dividend Yield4.56%5.89%5.86%5.31%
P/E Ratio-47.91527.1376.855,437.67
Price / Sales4.30236.57453.0397,249.19
Price / Cash1.1247.1437.2227.93
Price / Book0.205.1113.689.25
Net Income-£10.84M-£15.55M£3.29B£5.89B
7 Day Performance-11.95%3.37%-0.75%0.69%
1 Month Performance-11.19%1.95%3.84%44.83%
1 Year Performance-75.45%12.23%82.85%184.09%

Feedback Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDBK
Feedback
N/AGBX 11.71
-0.3%
N/A-73.9%£5.13M£1.19M-47.9124Earnings Report
High Trading Volume
RENX
Renalytix
N/AGBX 5.70
-2.6%
N/A-24.5%£18.88M£2.37M-35.63102
COG
Cambridge Cognition
N/AGBX 35
+2.9%
N/A-4.4%£14.65M£9.05M-921.0580Gap Up
INHC
Induction Healthcare Group
N/AGBX 9.75
flat
N/A+36.4%£9.00M£12.57M-1.7674
IQAI
IQ-AI
N/AGBX 0.80
flat
N/A-34.9%£1.77M£538.19K-13.676Gap Up
TRLS
Trellus Health
N/AGBX 0.78
-3.1%
N/A-49.2%£1.25M£114K-15.5031
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41M-15.0073
SENS
Sensyne Health
N/AN/AN/AN/A£583K£7.81M-0.0270Gap Down
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
CRW
Craneware
1.532 of 5 stars
GBX 2,137
-0.1%
GBX 2,725
+27.5%
+13.5%£756.71M£198.10M5,028.24734News Coverage
Analyst Forecast
INS
Instem
N/AN/AN/AN/A£199.62M£61.63M5,928.57500

Related Companies and Tools


This page (LON:FDBK) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners